Prostaglandin Derivatives and Platelet-specific Proteins During Transluminal Coronary Angioplasty
There is much speculation about the role of prostaglandins and thromboxanes in ischemic heart disease. These endogenous compounds are potent modulators of vascular smooth muscle tone and platelet aggregability. During platelet activation platelets generate a potent vasoconstrictor, thromboxane A2 (TXA2), whereas prostaglandin I2 (PGI2), produced by the vessel wall, is a potent vasodilator and inhibits platelet aggregation . Both PGI2 and TXA2 are unstable and spontaneously convert to the inactive metabolites 6-Oxo-prostaglandin F1 α (6-Oxo-PGF1 α;) and thromboxane B2 (TXB2), respectively [2, 7]. In addition, the measurement of plasma concentrations of β-thromboglobulin (βTG), a specific protein, which is extruded from well-defined platelet granules into the surrounding medium, might reflect in vivo platelet activation .
KeywordsCatheter EDTA Aspirin Heparin Syringe
Unable to display preview. Download preview PDF.
- 5.Moncada S, Vane JR (1979) Pharmacology and endogenous role’s of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293–331Google Scholar
- 6.Oates JA, Roberts LJ, Sweetnam BJ, Maas RL, Gerkens JF, Taber DF (1980) Metabolism of the prostaglandins and thromboxanes. In: Samuelson B, Ramwell PW, Paoletti R (eds) Advances in prostaglandin and thromboxane research. Raven Press, New York pp 35–41Google Scholar